A Single-Arm, Blinded, Fluorescent PSMA Histopathology Trial of AS1986NS

Sponsor: Antelope Surgical Solutions, Inc

Sponsor score: 0
Inactive

ClinicalTrials ID:NCT06906471

Patient View

This trial investigates the use of AS1986NS, a fluorescent drug administered as a single 100 µg IV dose, in patients with suspected prostate cancer requiring a standard multi-core biopsy. The study aims to enhance histopathological evaluation through PSMA-targeted fluorescence, potentially improving diagnostic accuracy in prostate cancer detection.

Patient Parameters

Program Overview

A Single-Arm, blinded, fluorescent PSMA histopathology trial of AS1986NS

Eligibility Criteria

Inclusion Criteria

  • suspected prostate cancer warranting standard of care multi-core prostate biopsy

Exclusion Criteria

  • Patients receiving same-day therapeutic Lutetium-177 or Actinium-225 PSMA receptor radiation isotope therapy treatment
  • Patients with pre-existing, impaired or abnormal hepatic function, renal function, cardiac function, and abnormal elevated temperature
  • Patients with a creatinine clearance cutoff (CrCl) of < 60 mL/min

Get This Program In Your Inbox

You can sign up and apply your patients for this program.